

## Biosimilar Pipeline Report December 2018

Pipeline Drug	Manufacturer	Current Status	Approval Date	Comments
1. filgrastim biosimilar	Adello Biologic	351(k) Filed	2018	Estimated Launch: TBD (FDA Approval) Innovator Brand: Neupogen (filgrastim)
2. pegfilgrastim biosimilar Lapelga INTP 5	Apotex Intas	351(k) Filed	2018	Estimated Launch: TBD (FDA Approval) Innovator Brand: Neulasta (pegfilgrastim)
3. filgrastim biosimilar Grastofil	Apotex Intas	351(k) Filed	2018	Estimated Launch: TBD (FDA Approval) Innovator Brand: Neupogen (filgrastim)
4. trastuzumab biosimilar Ontruzant SB3	Merck Samsung Bioepis	351(k) Filed	Jan. 2019	Estimated Launch: TBD (2019) Innovator Brand: Herceptin (trastuzumab)
5. trastuzumab biosimilar Trazimera PF-05280014	Pfizer	351(k) Filed	Feb. 2019	Estimated Launch: TBD (2019) Innovator Brand: Herceptin (trastuzumab)
6. bevacizumab biosimilar PF-06439535	Pfizer	351(k) Filed	June 2019	Estimated Launch: TBD (2019-2020) Innovator Brand: Avastin (bevacizumab)
7. adalimumab biosimilar Imraldi SB5	Biogen Samsung Bioepis	351(k) Filed	July 2019	Estimated Launch: June 30, 2023 Innovator Brand: Humira (adalimumab)
8. rituximab biosimilar PF-05280586	Pfizer	351(k) Filed	July 2019	Estimated Launch: TBD (2019) Innovator Brand: Rituxan (rituximab)
9. filgrastim biosimilar TX-01	Tanvex	351(k) Filed	10/01/2019	Estimated Launch: TBD (2019) Innovator Brand: Neupogen (filgrastim)
10. infliximab biosimilar ABP 710	Amgen	BLA Filed	10/17/2019	Estimated Launch: TBD (2019) Innovator Brand: Remicade (infliximab)

Pipeline Drug	Manufacturer	Current Status	Approval Date	Comments
11. etanercept-szszs Erelzi GP2015	Sandoz		8/30/2016	Estimated Launch: TBD (2019 - 2028) Innovator Brand: Enbrel (etanercept)
12. adalimumab-atto Amjevita ABP-501	Amgen		9/23/2016	Estimated Launch: Settlement: 01/31/2023  Innovator Brand: Humira (adalimumab)
13. adalimumab -adbm Cyltezo BI 695501	Boehringer		8/25/2017	Estimated Launch: TBD (2020-2023) Innovator Brand: Humira (adalimumab)
14. bevacizumab -awwb Mvasi ABP 215	Amgen Allergan		9/14/2017	Estimated Launch: TBD (Mid-2019) Innovator Brand: Avastin (bevacizumab)
15. trastuzumab- dkst Ogivri MYL-1401O	Mylan Biocon		12/1/2017	Estimated Launch: TBD (Mid 2019) Innovator Brand: Herceptin (trastuzumab)
16. infliximab-qbtX Ixifi PF-06438179	Pfizer		12/13/2017	Approval Date: No US launch Plans Innovator Brand: Remicade (infliximab)
17. adalimumab-adaz Hyrimoz GP2017	Sandoz		10/31/2018	Approval Date: Settlement: 09/30/2023 Innovator Brand: Humira (adalimumab)
18. pegfilgrastim-cbqv Udenyca CHS-1701	Coherus Biosciences		11/2/2018	Approval Date: TBD (Jan 2019) Innovator Brand: Neulasta (pegfilgrastim)
19. rituximab biosimilar Truxima CT-P10	Celltrion Teva Pharmaceutical		11/28/2018	Approval Date: TBD (2018-2019) Innovator Brand: Rituxan (rituximab)
20. trastuzumab biosimilar Herzuma CT-P06	Celltrion Teva Pharmaceutical		12/17/2018	Approval Date: TBD (2019) Innovator Brand: Herceptin (trastuzumab)